File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

TitleLansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use
Authors
Issue Date2002
PublisherMassachusetts Medical Society. The Journal's web site is located at http://content.nejm.org/
Citation
New England Journal Of Medicine, 2002, v. 346 n. 26, p. 2033-2038 How to Cite?
AbstractBackground: The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection in patients taking long-term low-dose aspirin is uncertain. Methods: We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H. pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications. Results: During a median follow-up of 12 months, 9 of the 61 patients in the placebo group (14.8 percent), as compared with 1 of the 62 patients in the lansoprazole group (1.6 percent), had a recurrence of ulcer complications (adjusted hazard ratio, 9.6; 95 percent confidence interval, 1.2 to 76.1). Of these 10 patients, 4 had evidence of a recurrence of H. pylori infection and 2 had taken nonsteroidal antiinflammatory drugs before the onset of complications. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups. Conclusions: In patients who had ulcer complications related to the long-term use of low-dose aspirin, treatment with lansoprazole in addition to the eradication of H. pylori infection significantly reduced the rate of recurrence of ulcer complications. Copyright © 2002 Massachusetts Medical Society.
Persistent Identifierhttp://hdl.handle.net/10722/43107
ISSN
2015 Impact Factor: 59.558
2015 SCImago Journal Rankings: 14.619
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, KCen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorChu, KMen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2007-03-23T04:39:00Z-
dc.date.available2007-03-23T04:39:00Z-
dc.date.issued2002en_HK
dc.identifier.citationNew England Journal Of Medicine, 2002, v. 346 n. 26, p. 2033-2038en_HK
dc.identifier.issn0028-4793en_HK
dc.identifier.urihttp://hdl.handle.net/10722/43107-
dc.description.abstractBackground: The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection in patients taking long-term low-dose aspirin is uncertain. Methods: We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H. pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications. Results: During a median follow-up of 12 months, 9 of the 61 patients in the placebo group (14.8 percent), as compared with 1 of the 62 patients in the lansoprazole group (1.6 percent), had a recurrence of ulcer complications (adjusted hazard ratio, 9.6; 95 percent confidence interval, 1.2 to 76.1). Of these 10 patients, 4 had evidence of a recurrence of H. pylori infection and 2 had taken nonsteroidal antiinflammatory drugs before the onset of complications. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups. Conclusions: In patients who had ulcer complications related to the long-term use of low-dose aspirin, treatment with lansoprazole in addition to the eradication of H. pylori infection significantly reduced the rate of recurrence of ulcer complications. Copyright © 2002 Massachusetts Medical Society.en_HK
dc.format.extent95647 bytes-
dc.format.extent27648 bytes-
dc.format.extent454989 bytes-
dc.format.extent3155 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/msword-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherMassachusetts Medical Society. The Journal's web site is located at http://content.nejm.org/en_HK
dc.relation.ispartofNew England Journal of Medicineen_HK
dc.rightsNew England Journal of Medicine. Copyright © Massachusetts Medical Society.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAnti-inflammatory agents, non-steroidal - adverse effectsen_HK
dc.subject.meshAnti-ulcer agents - therapeutic useen_HK
dc.subject.meshH(+)-k(+)-exchanging atpase - antagonists & inhibitorsen_HK
dc.subject.meshPeptic ulcer - chemically induced - microbiology - prevention & controlen_HK
dc.subject.meshEnzyme inhibitors - therapeutic useen_HK
dc.titleLansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin useen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0028-4793&volume=346&issue=26&spage=2033&epage=2038&date=2002&atitle=Lansoprazole+for+the+prevention+of+recurrences+of+ulcer+complications+from+long-term+low-dose+aspirin+useen_HK
dc.identifier.emailChu, KM: chukm@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityChu, KM=rp00435en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1056/NEJMoa012877en_HK
dc.identifier.pmid12087138-
dc.identifier.scopuseid_2-s2.0-0037182764en_HK
dc.identifier.hkuros83498-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037182764&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume346en_HK
dc.identifier.issue26en_HK
dc.identifier.spage2033en_HK
dc.identifier.epage2038en_HK
dc.identifier.isiWOS:000176411900003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridLam, SK=7402279800en_HK
dc.identifier.scopusauthoridChu, KM=7402453538en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridHui, WM=7103196477en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK
dc.identifier.citeulike2994400-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats